Immune Checkpoint Inhibitors and Infection: What Is the Interplay?

PAPADAKIS, MICHAIL; KARNIADAKIS, IOANNIS; MAZONAKIS, NIKOLAOS; AKINOSOGLOU, KAROLINA; TSIOUTIS, CONSTANTINOS; SPERNOVASILIS, NIKOLAOS

doi:10.21873/invivo.13346

Cited by 1 publication

(1 citation statement)

References 92 publications

(141 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most studied immunotherapy involves immune checkpoint inhibitors (ICIs). ICIs function by targeting specific proteins expressed on immune or cancer cells, thereby alleviating inhibitory signals that prevent the immune system from attacking cancer cells and augmenting the immune response against these cells ( 2 ). Key checkpoint proteins, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and programmed cell death ligands (PD-Ls), serve as primary targets for ICIs.…”

Section: Introductionmentioning

confidence: 99%

Exploring the potential of the TCR repertoire as a tumor biomarker (Review)

Huang,

He,

Yang

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

T cells play an important role in adaptive immunity. Mature T cells specifically recognize antigens on major histocompatibility complex molecules through T-cell receptors (TCRs). As the TCR repertoire is highly diverse, its analysis is vital in the assessment of T cells. Advances in sequencing technology have provided convenient methods for further investigation of the TCR repertoire. In the present review, the TCR structure and the mechanisms by which TCRs function in tumor recognition are described. In addition, the potential value of the TCR repertoire in tumor diagnosis is reviewed. Furthermore, the role of the TCR repertoire in tumor immunotherapy is introduced, and the relationships between the TCR repertoire and the effects of different tumor immunotherapies are discussed. Based on the reviewed literature, it may be concluded that the TCR repertoire has the potential to serve as a biomarker for tumor prognosis. However, a wider range of cancer types and more diverse subjects require evaluation in future research to establish the TCR repertoire as a biomarker of tumor immunity.

show abstract

Section: Introductionmentioning

confidence: 99%